Comparison

Liraglutide vs. Semaglutid

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Liraglutide

Liraglutide is a synthetic GLP-1 analog with 97% sequence identity to human GLP-1. A fatty-acid side chain (C16) on Lys-26 reversibly binds serum albumin and protects against DPP-4 degradation. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon secretion, delays gastric emptying and modulates central satiety.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Liraglutide	Semaglutid
Switzerland	—	Prescription
Germany	Prescription	Prescription
United States	Prescription	Prescription

Full entries

Frequently asked questions

What is the difference between Liraglutide and Semaglutid?: Liraglutide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Liraglutide or Semaglutid?: The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Liraglutide and Semaglutid in Germany and the United States?: Germany: Liraglutide — Prescription, Semaglutid — Prescription. United States: Liraglutide — Prescription, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.

Country

Liraglutide

Semaglutid

Switzerland

—

Prescription

Germany

Prescription

United States

Prescription

Frequently asked questions

What is the difference between Liraglutide and Semaglutid?

Liraglutide is classified as "Metabolic", while Semaglutid is classified as "Metabolic". Liraglutide: GLP-1 receptor agonist with a half-life of about 13 hours. The first daily (not weekly) modern GLP-1 RA — approved as Victoza for type 2 diabetes (2010) and Saxenda for obesity (2014). Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Liraglutide or Semaglutid?

The highest available evidence level is "Human RCT" for Liraglutide and "Human RCT" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Liraglutide and Semaglutid in Germany and the United States?

Germany: Liraglutide — Prescription, Semaglutid — Prescription. United States: Liraglutide — Prescription, Semaglutid — Prescription. These are factual summaries with source and review date on the individual pages.